Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, Healey LA, Kaplan SR, Liang MH, Luthra HS et al (1988) The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31:315–324
Article CAS PubMed Google Scholar
Bittner S, Knoll G, Fullsack S, Kurz M, Wajant H, Ehrenschwender M (2016) Soluble TL1A is sufficient for activation of death receptor 3. FEBS J 283:323–336
Article CAS PubMed Google Scholar
Bustamante MF, Garcia-Carbonell R, Whisenant KD, Guma M (2017) Fibroblast-like synoviocyte metabolism in the pathogenesis of rheumatoid arthritis. Arthritis Res Ther 19:110
Article PubMed PubMed Central Google Scholar
Greisen SR, Kragstrup TW, Thomsen JS, Hansen AS, Krishnamurthy A, Horslev-Petersen K, Hetland ML, Stengaard-Pedersen K, Ostergaard M, Ornbjerg LM et al (2020) Programmed death ligand 2 - a link between inflammation and bone loss in rheumatoid arthritis. J Transl Autoimmun 3:100028
Guo Y, Walsh AM, Canavan M, Wechalekar MD, Cole S, Yin X, Scott B, Loza M, Orr C, McGarry T et al (2018) Immune checkpoint inhibitor PD-1 pathway is down-regulated in synovium at various stages of rheumatoid arthritis disease progression. PLoS ONE 13:e0192704
Article PubMed PubMed Central Google Scholar
Hatachi S, Iwai Y, Kawano S, Morinobu S, Kobayashi M, Koshiba M, Saura R, Kurosaka M, Honjo T, Kumagai S (2003) CD4+ PD-1+ T cells accumulate as unique anergic cells in rheumatoid arthritis synovial fluid. J Rheumatol 30:1410–1419
Inaba K, Yashiro T, Hiroki I, Watanabe R, Kasakura K, Nishiyama C (2020) Dual roles of PU.1 in the expression of PD-L2: direct transactivation with IRF4 and indirect epigenetic regulation. J Immunol 205:822–829
Article CAS PubMed Google Scholar
Kanai T, Totsuka T, Uraushihara K, Makita S, Nakamura T, Koganei K, Fukushima T, Akiba H, Yagita H, Okumura K et al (2003) Blockade of B7–H1 suppresses the development of chronic intestinal inflammation. J Immunol 171:4156–4163
Article CAS PubMed Google Scholar
Karolova J, Radek M, Helman K, Spacek M, Trneny M, Klener P (2020) PD-1, PD-L1 and PD-L2 expression in mantle cell lymphoma and healthy population. Folia Biol (Praha) 66:117–122
Keir ME, Butte MJ, Freeman GJ, Sharpe AH (2008) PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol 26:677–704
Article CAS PubMed Google Scholar
Khan M, Zhao Z, Arooj S, Fu Y, Liao G (2020) Soluble PD-1: predictive, prognostic, and therapeutic value for cancer immunotherapy. Front Immunol 11:587460
Article CAS PubMed PubMed Central Google Scholar
Lazar-Molnar E, Yan Q, Cao E, Ramagopal U, Nathenson SG, Almo SC (2008) Crystal structure of the complex between programmed death-1 (PD-1) and its ligand PD-L2. Proc Natl Acad Sci U S A 105:10483–10488
Article CAS PubMed PubMed Central Google Scholar
Meng W, Zhu Z, Jiang X, Too CL, Uebe S, Jagodic M, Kockum I, Murad S, Ferrucci L, Alfredsson L et al (2017) DNA methylation mediates genotype and smoking interaction in the development of anti-citrullinated peptide antibody-positive rheumatoid arthritis. Arthritis Res Ther 19:71
Article PubMed PubMed Central Google Scholar
Messal N, Serriari NE, Pastor S, Nunes JA, Olive D (2011) PD-L2 is expressed on activated human T cells and regulates their function. Mol Immunol 48:2214–2219
Article CAS PubMed Google Scholar
Pawlowska A, Kwiatkowska A, Suszczyk D, Chudzik A, Tarkowski R, Barczynski B, Kotarski J, Wertel I (2021) Clinical and prognostic value of antigen-presenting cells with PD-L1/PD-L2 expression in ovarian cancer patients. Int J Mol Sci 22
Smolen JS, Aletaha D, Barton A, Burmester GR, Emery P, Firestein GS, Kavanaugh A, McInnes IB, Solomon DH, Strand V, Yamamoto K (2018) Rheumatoid arthritis. Nat Rev Dis Primers 4:18001
Smolen JS, Aletaha D, McInnes IB (2016) Rheumatoid arthritis. Lancet 388:2023–2038
Article CAS PubMed Google Scholar
Sun C, Mezzadra R, Schumacher TN (2018) Regulation and Function of the PD-L1 Checkpoint. Immunity 48:434–452
Article CAS PubMed PubMed Central Google Scholar
Tong M, Fang X, Yang J, Wu P, Guo Y, Sun J (2020) Abnormal membrane-bound and soluble programmed death ligand 2 (PD-L2) expression in systemic lupus erythematosus is associated with disease activity. Immunol Lett 227:96–101
Article CAS PubMed Google Scholar
Yamazaki T, Akiba H, Iwai H, Matsuda H, Aoki M, Tanno Y, Shin T, Tsuchiya H, Pardoll DM, Okumura K et al (2002) Expression of programmed death 1 ligands by murine T cells and APC. J Immunol 169:5538–5545
Article CAS PubMed Google Scholar
Yasuoka H, Asai A, Ohama H, Tsuchimoto Y, Fukunishi S, Higuchi K (2020) Increased both PD-L1 and PD-L2 expressions on monocytes of patients with hepatocellular carcinoma was associated with a poor prognosis. Sci Rep 10:10377
Article CAS PubMed PubMed Central Google Scholar
Zhang G, Hou J, Shi J, Yu G, Lu B, Zhang X (2008) Soluble CD276 (B7–H3) is released from monocytes, dendritic cells and activated T cells and is detectable in normal human serum. Immunology 123:538–546
Article CAS PubMed PubMed Central Google Scholar
Zhong X, Tumang JR, Gao W, Bai C, Rothstein TL (2007) PD-L2 expression extends beyond dendritic cells/macrophages to B1 cells enriched for V(H)11/V(H)12 and phosphatidylcholine binding. Eur J Immunol 37:2405–2410
留言 (0)